Get the Stockscreener App
35.10
4.59%
1.54
After Hours:
35.10
Supernus Pharmaceuticals Inc stock is traded at $35.10, with a volume of 1.68M.
It is up +4.59% in the last 24 hours and up +11.36% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$33.56
Open:
$32.83
24h Volume:
1.68M
Relative Volume:
2.75
Market Cap:
$1.97B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
32.82
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+6.85%
1M Performance:
+11.36%
6M Performance:
-8.52%
1Y Performance:
+17.71%
1-Day Range:
$32.83
$35.92
1-Week Range:
$32.53
$35.92
52-Week Range:
$27.05
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
35.10 | 1.88B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
What institutional investors are buying Supernus Pharmaceuticals Inc. stockStock Market Entry Points To Watch Now - jammulinksnews.com
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthFinancial News Entry Points Backed By Experts - jammulinksnews.com
Supernus Pharmaceuticals Stock Gains on Upgrade and Acquisition ProgressNews and Statistics - IndexBox
Cantor Fitzgerald upgrades Supernus Pharmaceuticals stock rating on Qelbree sales outlook - Investing.com Canada
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - FinancialContent
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
What are the latest earnings results for Supernus Pharmaceuticals Inc.Capitalize on emerging investment opportunities - jammulinksnews.com
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
Supernus-Sage acquisition clears antitrust hurdle as HSR waiting period expires - Investing.com India
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
What is the dividend policy of Supernus Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - jammulinksnews.com
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio growth with strategic plans - jammulinksnews.com
How many analysts rate Supernus Pharmaceuticals Inc. as a “Buy”Free Risk Assessment Services - jammulinksnews.com
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Unlock powerful market analysis and alerts - jammulinksnews.com
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - 富途牛牛
What institutions are buying Supernus Pharmaceuticals Inc. stock nowBreakthrough stock performance - jammulinksnews.com
What drives Supernus Pharmaceuticals Inc. stock priceDouble or triple returns - PrintWeekIndia
What analysts say about Supernus Pharmaceuticals Inc. stockRapid wealth creation - Autocar Professional
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - FinancialContent
What makes Supernus Pharmaceuticals Inc. stock attractive to long term investorsBreakout portfolio performance - jammulinksnews.com
Supremex Announces Date of Its 2025 Second Quarter Results Conference Call - Yahoo.co
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Published on: 2025-07-23 12:28:32 - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Nasdaq
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co
CNS Drug Leader Supernus Pharmaceuticals Sets Q2 2025 Earnings Call with CEO Presentation - Stock Titan
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):